Zydus Lifesciences will hold a meeting of the Board of Directors of the Company on 5 February 2025.Powered by Capital Market - Live

APL Apollo Tubes Ltd, Minda Corporation Ltd, PVR Inox Ltd, Biocon Ltd are among the other stocks to see a surge in volumes on BSE today, 07 January 2025.Zydus Lifesciences Ltd notched up volume of 2.94 lakh shares by 10:46 IST on BSE, a 11.29 fold spurt over two-week average daily volume of 26011 shares. The stock rose 4.80% to Rs.1,007.90. Volumes stood at 62509 shares in the last session.APL Apollo Tubes Ltd registered volume of 65965 shares by 10:46 IST on BSE, a 6.56 fold spurt over two-week average daily volume of 10052 shares. The stock slipped 0.26% to Rs.1,588.20. Volumes stood at 11138 shares in the last session.Minda Corporation Ltd witnessed volume of 64962 shares by 10:46 IST on BSE, a 3.51 times surge over two-week average daily volume of 18484 shares. The stock increased 5.03% to Rs.532.60. Volumes stood at 24483 shares in the last session.PVR Inox Ltd saw volume of 60872 shares by 10:46 IST on BSE, a 2.74 fold spurt over two-week average daily volume of 22213 shares. The stock dropped 5.42% to Rs.1,183.00. Volumes stood at 59039 shares in the last session.Biocon Ltd clocked volume of 3.45 lakh shares by 10:46 IST on BSE, a 2.67 times surge over two-week average daily volume of 1.29 lakh shares. The stock gained 7.06% to Rs.383.90. Volumes stood at 3.08 lakh shares in the last session.Powered by Capital Market - Live

The said product is for the treatment of Menkes disease. Sentynl's NDA is supported by positive topline clinical efficacy results for CUTX-101, demonstrating statistically significant improvement in overall survival for Menkes disease subjects who received early treatment with CUTX-101, with a nearly 80% reduction in the risk of death compared to an untreated historical control cohort. Median overall survival was 177.1 months for the CUTX-101 early treatment cohort compared to 16.1 months for the untreated historical control cohort. Punit Patel, president & CEO, Zydus Americas, 'The NDA acceptance of CUTX-101 marks an important step towards our vision to transform lives and meaningfully impact patients, caregivers, and the rare disease community at large. We remain committed to providing access to path-breaking discoveries that can address unmet needs globally, as evident in the potential impact of CUTX-101 on Menkes disease patients and their families.' Matt Heck, president & CEO, Sentynl, 'Menkes disease presents a difficult journey for patients and their caregivers, as ATP7A mutations impact the transport of copper to a range of organs and systems, such as the lungs, brain and heart. With no known cure or current FDA-approved treatments, death typically occurs between 2 to 3 years of age. We are eager for the FDA to review our application for CUTX-101, which has the potential to be the first FDA-approved therapy for this devastating condition.' Lindsay A. Rosenwald, M.D, chairman, president and chief executive officer, Fortress and Chairmanof Cyprium, 'We congratulate Sentynl on the NDA acceptance for filing and review of CUTX-101, a program that Cyprium advanced and proudly supports, The drug has a demonstrated safety and efficacy profile for the treatment of Menkes disease and, if approved, CUTX-101 will fill a significant unmet need for children suffering from this rare, fatal pediatric disease.' Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit increased 13.8% to Rs 911.20 crore in Q2 FY25 as against Rs 800.70 crore posted in Q2 FY24. Revenue from operations jumped 20.1% to Rs 5,113.60 crore in the quarter ended 30 September 2024.Powered by Capital Market - Live

Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences (Zydus Group), and Fortress Biotech, Inc. (Nasdaq: FBIO) (Fortress) announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and Priority review Sentynl's New Drug Application (NDA) for CUTX-101, the product candidate for the treatment of Menkes disease. Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A. Recent estimates suggest a prevalence of 1 in 34,810 to as high as 1 in 8,664 live male births. Sentynl's NDA is supported by positive topline clinical efficacy results for CUTX-101, demonstrating statistically significant improvement in overall survival for Menkes disease subjects who received early treatment with CUTX-101, with a nearly 80% reduction in the risk of death compared to an untreated historical control cohort. Median overall survival was 177.1 months for CUTX-101 early treatment cohort compared to 16.1 months for the untreated historical control cohort. 'The NDA acceptance of CUTX-101 marks an important step towards our vision to transform lives and meaningfully impact patients, caregivers, and the rare disease community at large,' said Punit Patel, President and CEO, Zydus Americas. 'We remain committed to providing access to path-breaking discoveries that can address unmet needs globally, as evident in the potential impact of CUTX-101 on Menkes disease patients and their families.' 'Menkes disease presents a difficult journey for patients and their caregivers, as ATP7A mutations impact the transport of copper to a range of organs and systems, such as the lungs, brain and heart. With no known cure or current FDA-approved treatments, death typically occurs between 2 to 3 years of age,' said Matt Heck, President & Chief Executive Officer of Sentynl. 'We are eager for the FDA to review our application for CUTX-101, which has the potential to be the first FDA-approved therapy for this devastating condition.'Powered by Capital Market - Live

Zydus Lifesciences has appointed Vikram Shukla as a President-Parenteral Operations and designated as the Senior Management Personnel. Powered by Capital Market - Live

In September 2024, Zydus Lifesciences intimated about execution of Business Transfer Agreement (BTA) to purchase the API business of Sterling Biotech (SBL), subject to certain conditions precedent and closing date adjustments as provided in the BTA, with effect from such date, and in such manner and on the terms and conditions as mentioned in the BTA. This transaction was expected to be completed by 31 December 2024. Now, SBL is still in the process of completing certain conditions precedents of the BTA and is expected to take some more time to complete the same. In view of the same, and as per the terms and conditions of the BTA, the Company and SBL have mutually decided to extend the date of closing upto 31 March 2025. The Company and SBL have today, i.e. 27 December 2024, executed a letter to extend the date of completion as above. In view of the same, the transaction is expected to be completed on or before 31 March 2025. Powered by Capital Market - Live

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture Lidocaine and Prilocaine Cream USP, 2.5%/2.5% (USRLD: EMLA' Cream, 2.5%/2.5%). Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia. Lidocaine and Prilocaine cream will be produced at the Group's topical manufacturing site at Changodar, Ahmedabad. Lidocaine and Prilocaine cream had annual sales of USD 22.05 mn in the United States (IQVIA MAT October 2024). The group now has 412 approvals and has so far filed over 473* ANDAs since the commencement of the filing process in FY 2003-04. Powered by Capital Market - Live

Lidocaine and Prilocaine Cream USP is indicated as a topical anaesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anaesthesia. Lidocaine and Prilocaine cream will be produced at the Group's topical manufacturing site at Changodar, Ahmedabad. Lidocaine and Prilocaine cream had annual sales of $22.05 million in the United States (IQVIA MAT October 2024). The group now has 412 approvals and has so far filed over 473 ANDAs since the commencement of the filing process in FY 2003-04. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The company's consolidated net profit increased 13.8% to Rs 911.20 crore in Q2 FY25 as against Rs 800.70 crore posted in Q2 FY24. Revenue from operations jumped 20.1% to Rs 5,113.60 crore in the quarter ended 30 September 2024. The scrip rose 0.52% to Rs 984.20 on the BSE. Powered by Capital Market - Live

Zydus Lifesciences announced that Zydus Animal Health and Investments, a wholly owned subsidiary (ZAHL) had acquired 65,06,500 equity shares of Re. 1 each fully paid-up, representing 6.5% of the total paid-up share capital (Sale Shares) of Mylab Discovery Solutions (Mylab) from Rising Sun Holding (RHSPL) at an agreed consideration of Rs. 106 crore vide a Share Purchase Agreement (SPA) executed by ZAHL, RHSPL and Mylab on 23 June 2023. Now, pursuant to the terms and conditions of the SPA, ZAHL has exercised its Put Option right to sell the Sale Shares back to RHSPL and RHSPL has agreed to acquire the Sale Shares at the original consideration amount i.e. Rs. 106 crore. The Board of Directors of ZAHL at their meeting held today i.e. 16 December 2024, approved the disinvestment of Sale Shares, as per the terms and conditions of the SPA. Post that, ZAHL, RSHPL and Mylab have executed the termination deed. Powered by Capital Market - Live

Zydus Lifesciences Ltd rose for a third straight session today. The stock is quoting at Rs 984.6, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.63% on the day, quoting at 24428.3. The Sensex is at 80776.82, up 0.66%. Zydus Lifesciences Ltd has dropped around 1.98% in last one month. Meanwhile, Nifty Pharma index of which Zydus Lifesciences Ltd is a constituent, has dropped around 0.61% in last one month and is currently quoting at 22450.2, up 0.22% on the day. The volume in the stock stood at 6.68 lakh shares today, compared to the daily average of 11.59 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 986.9, up 0.7% on the day. Zydus Lifesciences Ltd is up 55.45% in last one year as compared to a 18.09% gain in NIFTY and a 38.64% gain in the Nifty Pharma index.The PE of the stock is 22.53 based on TTM earnings ending September 24.Powered by Capital Market - Live